Story perspectives

Novo Nordisk Invests $2.1B in GLP-1 Delivery Partnership

2/26/2026

Summary

Story summary

Novo Nordisk will invest up to $2.1 billion in a Vivtex partnership to improve oral delivery of glucagon-like peptide-1 (GLP-1) therapies, including Wegovy and Ozempic.
Vivtex, a Boston startup founded by MIT scientists, has developed a screening platform for absorption in the gastrointestinal tract.
The collaboration could yield GLP-1 drugs or other classes.
Despite leadership changes and Eli Lilly competition, Novo Nordisk aims to strengthen its weight loss market.

1 of 1

Story summary

Novo Nordisk will invest up to $2.1 billion in a Vivtex partnership to improve oral delivery of glucagon-like peptide-1 (GLP-1) therapies, including Wegovy and Ozempic.
Vivtex, a Boston startup founded by MIT scientists, has developed a screening platform for absorption in the gastrointestinal tract.
The collaboration could yield GLP-1 drugs or other classes.
Despite leadership changes and Eli Lilly competition, Novo Nordisk aims to strengthen its weight loss market.